Various studies indicate that the combination of an angiogenesis inhibitor (bevacizumab) and an immunotherapeutic (atezolizumab) in tumor therapy could have a clinical benefit with acceptable tolerability. This combination will therefore now be investigated in AGO-OVAR. Around 200 centers worldwide, including 13 centers in Switzerland, will participate in the trial, with the aim of enrolling 664 patients.

Further information on the AGO-OVAR trial can be found here.